The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perfume trial: Phase II trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer.
 
Tomoyuki Satake
Honoraria - AstraZeneca
Research Funding - Nihon Servier (Inst)
 
Makoto Ohno
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Novocure (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PPD Global (Inst); Sumitomo Pharma Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Chiharu Mizoguchi
No Relationships to Disclose
 
Satoshi Kawashima
No Relationships to Disclose
 
Ryo Sadachi
No Relationships to Disclose
 
Masahiro Yoshioka
No Relationships to Disclose
 
Ichiro Kinoshita
Honoraria - Bayer; Chugai Pharma; Guardant Health; Konica Minolta; MSD; Novartis; Pfizer; Takeda
Research Funding - Daiich Sankyo; Eisai; Konica Minolta
 
Keigo Komine
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte Japan; MSD
Research Funding - Janssen (Inst)
 
Kenji Tsuchihashi
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma
 
Chigusa Morizane
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Guardant Health; Incyte Japan; MSD K.K.; Myriad Genetics; Novartis; SERVIER; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Merck; MSD K.K.; Pfizer; Revolution Medicines; SERVIER; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare (Inst); Eisai (Inst); EPS Corporation (Inst); Hitachi (Inst); LabCorp (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst)